**All Interactions with Etravirine (Intelence)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Artemether[607](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#607)  (Coartem) | Artemether/lumefantrine 80/480 mg | 200 mg BID | Artemether AUC: decreased 38%; Lumefantrine AUC: decreased 13% | No significant change | Decreased antimalarial effects | - | Use with caution; avoid if possible |
| Atazanavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (ATV)(Reyataz) | 300 mg QD with 100 mg ritonavir QD | - | Atazanavir AUC: decreased 14%; Cmin: decreased 38% | Etravirine AUC: increased 30%; Cmax: increased 30%; Cmin: decreased 26% | Possibly increased etravirine effects | - | Do not coadminister |
| Atazanavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (ATV)(Reyataz) | 400 mg QD | - | Atazanavir AUC: decreased 17%; Cmin: decreased 47% | Etravirine AUC: increased 50%; Cmax: increased 47%; Cmin: increased 58% | Possibly increased etravirine effects; decreased atazanavir effects | Inhibition of etravirine metabolism; induction of CYP450 3A4 by etravirine | Do not coadminister |
| Atorvastatin[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405) | 40 mg QD | - | Atorvastatin AUC: decreased 37% 2-hydroxyatorvastatin AUC: increased 27%; Cmax: increased 76% | No significant change | Decreased atorvastatin effects | Induction of CYP450 3A4 by etravirine | Consider low dose atorvastatin and titrate to effect; monitor for myopathy |
| Boceprevir[615](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#615)  (Victrelis) | - | - | - | - | Decreased etravirine effects | - | Dose adjustment not established; use with caution |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Clarithromycin[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Biaxin) | 500 mg BID | - | Clarithromycin AUC: decreased 37%; Cmax: decreased 34%; Cmin: decreased 53%; 14-hydroxyclarithromycin AUC: increased 21%; Cmax: increased 33% | Etravirine AUC: increased 42%; Cmax: increased 46%; Cmin: increased 46% | Increased etravirine effects; decreased clarithromycin effects | Induction of CYP450 3A4 by etravirine; inhibition by clarithromycin | Avoid combination if possible; consider use of azithromycin  *Alternative Agents*:  **Azithromycin** |
| Clopidogrel[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Plavix) | - | - | - | - | Possibly decreased clopidogrel effects | Activation of clopidogrel to its active metabolites may be decreased by etravirine | Avoid combination; consider alternative agents |
| Darunavir[410](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#410),[161](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#161),[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (DRV)(Prezista) | - | 200 mg BID | Darunavir AUC: increased 15% | Etravirine AUC: increased 80%; Cmax: increased 81%; Cmin: increased 67% (compared to etravirine 100 mg BID) | - | - | No dose adjustment necessary |
| Darunavir[410](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#410),[161](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#161),[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (DRV)(Prezista) | 600 mg BID with 100 mg ritonavir BID | 100 mg BID | No significant change | Etravirine AUC: decreased 37%; Cmax: decreased 32%; Cmin: decreased 49% | - | Induction of CYP450 3A4 by etravirine | No dose adjustment necessary |
| Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#727)  (Viekira) | - | - | - | - | Potential decrease in anti-HCV efficacy | Potential CYP3A4 induction by etravirine | Do not coadminister |
| Didanosine[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (ddI)(Videx) | 400 mg QD | - | No significant change | Etravirine Cmax: increased 16% | - | - | No dose adjsutment |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Dolutegravir[641](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#641)  (Tivicay) | 50 mg QD | 200 mg BID | Dolutegravir AUC: decreased 71%; Cmin: decreased 88% | - | Potentially reduced dolutegravir effectiveness | - | Do not coadminister etravirine with dolutegravir unless boosted atazanavir, darunavir or lopinavir are also being used concomitantly. |
| Dolutegravir[641](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#641)  (Tivicay) | 50 mg QD | 200 mg BID with darunavir/ritonavir 600/100 mg BID | Dolutegravir AUC: decreased 25%; Cmin: decreased 37% | - | Potentially reduced dolutegravir effectiveness | - | If no INSTI resistance, no dose adjustment necessary. If known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID |
| Dolutegravir[641](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#641)  (Tivicay) | 50 mg QD | 200 mg BID with lopinavir/ritonavir 400/100 mg BID | Dolutegravir AUC increased 11%; Cmin: increased 28% | - | Potentially reduced dolutegravir effectiveness | - | If no INSTI resistance, no dose adjustment necessary. If known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID |
| Efavirenz[407](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#407)  (EFV)(Sustiva) | 600 mg QD | - | - | Etravirine AUC: decreased 41% | Decreased etravirine and efavirenz effects | Induction of CYP450 3A4 by etravirine and efavirenz | Do not coadminister |
| Elbasvir/grazoprevir[733](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#733),[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#727)  (Zepatier) | - | - | - | - | Potentially decreased elbasvir, grazoprevir levels expected | Expected CYP3A4 induction by etravirine | Contraindicated: Do not coadminister. Minimal or no data to guide interaction. Risks likely to outweigh benefits. |
| Elvitegravir/cobicistat[647](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#647),[639](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#639)  (Stribild) | Elvitegravir 150 mg QD | 200 mg BID with ritonavir 100 mg QD | No significant change | No significant change | Potentially decreased or increased elvitegravir, cobicistat and/or etravirine effects | - | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ethinyl estradiol/norethindrone acetate[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (others)(Ortho-Novum) | 0.035 mg EE/1 mg NE QD | - | Ethinyl estradiol AUC: increased 22%; Cmax: increased 33%; Norethindrone Cmin: decreased 22% | - | - | - | No dose adjustment necessary |
| Fluconazole[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405),[435](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#435)  (Diflucan)(Diflucan) | 200 mg QAM | 200 mg BID | No significant change | Etravirine AUC: increased 86%; Cmax: increased 75%; Cmin: increased 109% | Increased etravirine effects | Inhibition of CYP450 3A4 by fluconazole | Dose adjustment not established |
| Fosamprenavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (FPV)(Lexiva) | 700 mg BID with 100 mg ritonavir BID | - | Fosamprenavir AUC: increased 69%; Cmax: increased 62%; Cmin: increased 77% | - | Increased fosamprenavir effects | Inhibition of CYP450 by etravirine | Do not coadminister |
| Indinavir[407](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#407)  (IDV)(Crixivan) | - | - | Indinavir AUC: decreased 46% | Etravirine AUC: increased 51% | Decreased indinavir effects | - | Do not coadminister |
| Itraconazole[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Sporanox)(Sporanox) | - | - | Possibly decreased itraconazole levels | Possibly increased etravirine effects | Decreased itraconazole effects | - | - |
| Lopinavir/ritonavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405),[434](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#434)  (LPV/r)(Kaletra) | 400/100 mg BID | 200 mg BID | Lopinavir Cmin: decreased 20%; Ritonavir Cmax: decreased19% | Etravirine AUC: decreased 35%; Cmax: decreased 30%; Cmin: decreased 45% | Potentially decreased etravirine effects | Potential induction of CYP450 3A4, 2C9 and 2C19 by lopinavir/ritonavir | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Lumefantrine[607](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#607)  (Coartem) | Artemether/Lumefantrine 80/480 mg | 200 mg BID | Lumefantrine AUC: decreased 13% | No significant effect | Decreased antimalarial effects | - | Use with caution; avoid if possible. |
| Maraviroc[631](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#631)  (MVC)(Selzentry) | 150 mg BID | 200 mg BID with darunavir/ritonavir 600/100 mg BID | Maraviroc AUC: increased 3.10 fold; Cmax: increased 1.76 fold; Cmin: increased 5.27 fold | - | Increased maraviroc effects | - | No dose adjustment necessary; utilize maraviroc 150 mg BID when combined with etravirine AND darunavir/ritonavir |
| Maraviroc[1](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#1)  (MVC)(Selzentry) | 300 mg BID | 200 mg BID with darunavir/ritonavir 600/100 mg BID | Maraviroc AUC: increased 210%; Cmax: increased 77%; Cmin: increased 430% | No significant change on etravirine, darunavir or ritonavir pharmacokinetics | Increased maraviroc effects | Inhibition of CYP450 3A4 by darunavir/ritonavir | Decrease maraviroc to 150 mg BID |
| Maraviroc[1](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#1)  (MVC)(Selzentry) | 300 mg BID | 200 mg BID | Maraviroc AUC: decreased 53%; Cmax: decreased 60%; Cmin: decreased 39% | No significant change | - | Induction of CYP450 3A4 by etravirine | Increase maraviroc to 600 mg BID when used with etravirine |
| Maraviroc[631](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#631)  (MVC)(Selzentry) | 300 mg BID | 200 mg BID | Maraviroc AUC: decreased 53%; Cmax: decreased 60%; Cmin: decreased 39% | - | Decreased maraviroc effects | Induction of CYP450 3A4 by etravirine | Increase maraviroc to 600 mg BID when combined with etravirine |
| Methadone[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Dolophine)(Dolophine) | 60-130 mg QD | - | R-methadone: no significant effect; S-methadone: no significant effect | - | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nevirapine[407](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#407)  (NVP)(Viramune) | - | - | - | Etravirine AUC: decreased 55% | Decreased etravirine and nevirapine effects | - | - |
| Omeprazole[404](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#404),[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Prilosec)(Prilosec) | 40 mg QD x 11 days | 100 mg x 1 | - | Etravirine AUC: increased 41%; Cmax: increased 17% | - | - | No dose adjustment necessary |
| Paroxetine[169](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#169),[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Paxil)(Paxil) | 20 mg QD | 125 mg BID | No significant change | No significant change | - | - | No dose adjustment necessary |
| Posaconazole[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Noxafil) | - | - | - | Possibly increased etravirine levels | - | - | - |
| Raltegravir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (RAL)(Isentress) | 400 mg BID | - | Raltegravir Cmin: decreased 34% | Etravirine Cmin: increased 17% | - | - | No dose adjustment necessary |
| Raltegravir[433](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#433)  (RAL)(Isentress) | 400 mg BID | 200 mg BID | Raltegravir Cmin: decreased 34% | Etravirine Cmin: increased 17% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Etravirine** | **Effect on Drug Levels** | **Effect on Etravirine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ranitidine[404](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#404),[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Zantac)(Zantac) | 150 mg BID x 11 days | 100 mg x 1 | - | No significant change | - | - | No dose adjustment necessary |
| Rifabutin[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Mycobutin)(Mycobutin) | 300 mg QD | - | Rifabutin AUC: decreased 17%; Cmin: decreased 24%; 25-O-desacetylrifabutin AUC: decreased 17%; Cmax: decreased 15%; Cmin: decreased 22% | Etravirine AUC: decreased 37%; Cmax: decreased 37%; Cmin: decreased 35% | Decreased rifabutin effects | Induction of CYP450 by etravirine | If administered with etravirine and NO protease inhibitor, rifabutin coadministration is acceptable. If etravirine and a protease inhibitor are used together, consider alternate agents to rifabutin if at all possible. |
| Ritonavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (RTV)(Norvir) | 600 mg BID | - | - | Etravirine AUC: decreased 46%; Cmax: decreased 32% | - | Induction of CYP450 by ritonavir | - |
| Saquinavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (SQV)(Fortovase, Invirase) | 1000 mg BID with 100 mg ritonavir BID | - | Saquinavir Cmin: decreased 20% | Etravirine AUC: decreased 33%; Cmax: decreased 37%; Cmin: decreased 29% | - | - | No dose adjustment necessary |
| Sildenafil[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (Viagra) | 50 mg x 1 | - | Sildenafil AUC: decreased 57%; Cmax: decreased 45% | - | Decreased sildenafil effects | Induction of CYP450 3A4 by etravirine | No dose adjustment necessary |
| Telaprevir[627](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#627)  (Incivek) | 750 mg Q8H | 200 mg BID | Telaprevir AUC: decreased 16%, Cmin: decreased 25% | No significant change | - | - | No dose adjustment necessary |
| Tenofovir disoproxil fumarate[429](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#429)  (TDF)(Viread) | 300 mg QD | 200 mg BID | Tenofovir AUC: increased 15%; Cmin: increased 19%; Cmax: increased 15% | Etravirine AUC: decreased 19%; Cmin: decreased 18%; Cmax: decreased 19% | - | - | No dose adjustment necessary |
| Tipranavir[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (TPV)(Aptivus) | 500 mg BID with 200 mg ritonavir BID | - | Tipranavir AUC: increased 18%; Cmin: increased 24% | Etravirine AUC: decreased 76%; Cmax: decreased 71%; Cmin: decreased 82% | Decreased etravirine effects | Induction of CYP450 3A4 by tipranavir | Do not coadminister |
| Voriconazole[435](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#435),[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=1&post=4#405)  (VFend)(VFend) | 200 mg BID | 200 mg BID | Voriconazole Cmin: increased 23% | Etravirine AUC: increased 36%; Cmin: increased 52%; Cmax: increased 26% | Possibly increased etravirine effects | Inhibition of CYP450 3A4 by voriconazole | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 1: | Davis J, Scholler-Gyure M, Kakuda TN, et al. An open randomized two period crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/DRV/r on the steady state pharmacokinetics of oral maraviroc in healthy subjects [abstract P 4.3/02]. 11th European AIDS Conference; 2007 October 24-27; Madrid, Spain. |
| 161: | Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; April 2010. |
| 169: | Scholler-Gyure M, Kakuda TN, Bollen S, et al. No pharmacokinetic interaction between TMC125 and paroxetine in HIV-negative volunteers [abstract P4.3/01]. 11th European AIDS Conference; 2007 October 24-27; Madrid, Spain. |
| 404: | Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etraviribne (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers. Br J Pharmacol 2008; 66: 508-16. |
| 405: | Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; 2010. |
| 407: | Baede P, Piscitelli S, Graham N, et al. Drug Interactions with TMC125, a Potent Next Generation NNRTI. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract A-1827. |
| 410: | Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789-96. |
| 429: | Scholler-Gyure M, Debroye C, Woodfall B, et al . Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate [poster A-371]. Poster presentation at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-“30, 2006. |
| 433: | Anderson MS, Kakuda TM, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegavir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228-32. |
| 434: | Scholler-Gyure M, Kakuda TN, Akuma SH, et al. Pharmacokinetic interaction between etravirine and lopinavir/ritonavir [abstract A1-1298]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, 2009. San Francisco, CA. |
| 435: | Scholler-Gyure M, Kaduda TN, Van Solingen-Ristea R, et al. Pharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers [abstract A1-1299]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, 2009. San Francisco, CA. |
| 607: | Kakuda T, Jarus-Dziedzic K, DeMasi R, et al. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a randomized trial [abstract O-05]. Rev Antiviral Ther Infect Dis 2012; 3: 7. |
| 615: | Hammond KP, Wolfe P, Burton JR, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers [abstract O-015]. 13th Intl Workshop on Clin Pharmacol HIV Ther April 18, 2012; Barcelona, Spain. |
| 627: | Kakuda T, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial [abstract O-18]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012. Barcelona, Spain. |
| 631: | Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug intaraction trials. Antimicrob Agent Chemother 2011; 55: 2290-96. |
| 639: | DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Feb 12, 2013. |
| 641: | Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; Sept 2013. |
| 647: | Ramanathan S, West S, Kakuda TN, Mack R, Holmes C, Kearney BP. Lack of clinically relevant drug interactions between ritonavir-boosted elvitegravir and TMC125 [poster H-1049]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 17-20, 2007. Chicago, IL. |
| 727: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |
| 733: | Unique Patient Populations: Patients with HIV/HCV Co-infection. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases. Available at http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection |